Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim has announced a Phase III trial of its investigational lung disease drug nerandomilast has met its primary endpoint. Image credit: Tada Images /
Boehringer Ingelheim has announced a Phase III trial of its investigational lung disease drug nerandomilast has met its primary endpoint. Image credit: Tada Images /
Our guts are home to trillions of bacteria, and research over the last few decades has established how essential they are to our physiology –
The study found eight rare diseases associated with increased risk of Covid-19-related mortality. Credit: imageBROKER/Berit Kessler via Getty Images. Researchers in the UK are calling
Older adults who didn’t have enough savings to cover emergency expenses during the early months of the COVID-19 pandemic faced another surprising problem: higher levels
This story originally appeared in STAT’s sister publication, The Boston Globe. Mass General Brigham said Monday it will let go of hundreds of employees in
Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. The Peterson Health Technology Institute launched a
As the medical technology industry’s latest earnings season has unfolded, acquisitions and a business separation have emerged as a theme. In one of the biggest
Dive Brief: The Food and Drug Administration published an early alert on Thursday about a BD device linked to 30 serious injuries and four deaths.
Attorneys general representing 22 states sued the Trump administration on Monday, asking a federal judge to temporarily block a major policy change by the National
File this under ‘Now you see them, now you don’t.” One might think that a pharmaceutical ingredients company that boasts clients in 80 countries, certification